IPO Anniversary BioVersys at SIX
•February 9, 2026
0
Why It Matters
The progress accelerates a critical pipeline against antibiotic resistance, offering investors exposure to a high‑need therapeutic area while addressing a looming public‑health crisis.
Key Takeaways
- •BioVersys marks one year listed on SIX Swiss exchange
- •Antibiotic resistance threatens oncology outcomes, driving urgent drug development
- •BV100 phase‑2 cut mortality by 50%, poised for phase‑3
- •New partnership with Japan’s Shionogi expands early‑stage pipeline
- •Listing provides capital, visibility, and broader investor access for growth
Summary
BioVersys commemorated its first anniversary on the SIX Swiss Exchange, reaffirming its mission to combat drug‑resistant bacterial infections. The company highlighted how antibiotic resistance now jeopardizes advances such as oncology therapies, underscoring the urgency of new antibiotics.
The listing has amplified BioVersys’ visibility, granting access to international banks, analysts, and a broader investor base. Capital raised is earmarked for advancing its pipeline, notably BV100, which cut mortality by 50% in Phase 2 and is slated for a global Phase 3 trial.
2025 milestones included a new collaboration with Japan’s Shionogi on an early‑stage program and continued work with GSK on Alpectia. The company also initiated the Phase 3 study for BV100, positioning the drug closer to regulatory approval.
These developments signal a compelling investment case and promise expanded treatment options for patients facing resistant infections, with patient recruitment for Phase 3 slated for 2026.
Original Description
On 7 February, SIX proudly mark one year since BioVersys joined SIX Swiss Exchange, strengthening Switzerland’s position as a leading hub for biotech innovation and life‑science investment.
To reflect on this milestone, Marc Gitzinger, CEO of BioVersys, shares his experience from the company’s first year as a listed biotech - a year defined by scientific progress, global visibility, and advancing the fight against drug‑resistant bacterial infections.
0
Comments
Want to join the conversation?
Loading comments...